U.S. Preventive Services Task Force Faces Year-Long Halt in Voting Meetings Amidst Leadership Changes
The U.S. Preventive Services Task Force (USPSTF), a federal panel responsible for issuing evidence-based recommendations on preventive health services, has not held an official voting meeting in approximately one year, with its last session occurring in March 2025. The panel, which typically meets three times annually, is also operating with a reduced membership, and its output of new guidelines has significantly decreased. This period of inactivity coincides with leadership changes within the Department of Health and Human Services (HHS).
About the USPSTF: Mandate and Broad Impact
Established in 1984, the USPSTF is an independent panel composed of 16 volunteer medical and public health experts. Its primary role is to review scientific research and provide recommendations on preventive care services, such as cancer screenings, sexually transmitted infection (STI) testing, and counseling.
Under the Affordable Care Act (ACA), services receiving an 'A' or 'B' grade from the task force must be covered at no cost by most private insurers, Medicaid, and Medicare programs.
This provision impacts over 150 million privately insured individuals, 20 million Medicaid adults, and 61 million Medicare adults.
The task force currently has 54 such recommendations. The panel's work is designed to be insulated from political influence, providing non-biased, science-based advice.
Operational Delays and Reduced Membership
The USPSTF typically convenes in March, July, and November. Following its last meeting in March 2025, the July meeting was canceled, and the November meeting was scrapped due to a government shutdown. No meeting for the current March has been publicly announced, though HHS stated the March meeting would be rescheduled. While the panel continues to hold virtual discussions most weeks, official votes on recommendations typically occur during the three main meetings.
The task force is currently operating with 11 members, down from its usual 16. Five members' terms expired at the end of last year or on January 1 and have not been publicly replaced by the HHS secretary.
Significant Drop in Output and Pending Recommendations
The task force issued approximately five new guidelines last year, a decrease from its typical annual output of 20 to 25 recommendations. This represents a significant drop from its typical annual output. Several topics remain in various stages of development, including draft recommendation development or research plan phases. These include screenings for autism spectrum disorder, breast cancer medication, chronic kidney disease, and behavioral counseling for STIs. Four topics are awaiting finalization of draft recommendations, such as the self-collection of human papillomavirus (HPV) testing for cervical cancer. USPSTF recommendations are typically reviewed every five years to incorporate new research.
The task force also did not submit its annual report to Congress last year, a report that typically informs National Institutes of Health grant decisions. Reports have indicated turnover among the Agency for Healthcare Research and Quality (AHRQ) staff, who provide essential support for the task force's evidence reviews.
Context of HHS Leadership Changes
The USPSTF is convened by the Agency for Healthcare Research and Quality (AHRQ), which falls under the Department of Health and Human Services (HHS). This period of reduced activity coincides with changes initiated by Health Secretary Robert F. Kennedy Jr. Kennedy possesses the authority to appoint and dismiss USPSTF members.
Under Secretary Kennedy Jr.'s tenure, other federal advisory groups have also experienced changes:
- In June, all members of the Advisory Committee on Immunization Practices (ACIP) were replaced.
- The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has experienced a reduction in public meetings.
Reports from July indicated that Secretary Kennedy Jr. had privately criticized the USPSTF, and some individuals familiar with internal discussions reported he was considering removing all of its members. In response, the American Medical Association (AMA) urged Secretary Kennedy Jr. in a letter dated July 27 to maintain the panel's existing structure. An HHS spokesperson has not provided comments on potential changes to the task force or its future meeting schedule.
Reported Concerns and Potential Implications
Medical and legal experts have expressed concerns regarding the task force's current operational status. Dr. Aaron Carroll, CEO of AcademyHealth, noted that while the USPSTF's elimination requires congressional action, its effectiveness can be compromised through delayed appointments, work slowdowns, changes to standards, or reduced staff capacity. Dr. Alex Krist, a former task force chair, stated that the lack of meetings and updates hinders the ability to adapt screening and treatment recommendations to evolving medical knowledge and technology.
Commentators, including Dr. Robert Lawrence, the task force's first chair, and Dr. Steven Woolf, its first scientific adviser, have stated that changes to the task force could jeopardize millions of Americans' access to free preventive services and could erode trust in evidence-based policy. They also noted that limiting the task force's budget and staff could effectively disable its function. Legal experts have emphasized that politicizing the panel could undermine its function and reduce clinicians' inclination to follow its guidance.
The panel previously faced political challenges when conservative groups sued HHS over its "A" rating for the HIV prevention pill PrEP. The Supreme Court ultimately sided with the federal government, preserving the ACA’s requirement for insurers to cover services recommended by the panel.